Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 27'th Apr 2021
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference
Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?
12:47pm, Monday, 26'th Apr 2021
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.
INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) an
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatit
Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study
10:32am, Tuesday, 20'th Apr 2021
Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.
WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)---- $INCY--First Patient Dosed in P3 inMIND Study Adding Tafasitamab + Lenalidomide to Rituximab in Relapsed or Refractory Follicular or M
Incyte: What Falling Off A (Patent) Cliff Looks Like
09:30am, Friday, 16'th Apr 2021
A better understanding is needed of the financial implications for Incyte with its major product, Jakafi, facing LOE in 2027. Analysis indicates there's considerable uncertainty among analysts as to I
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
07:41am, Thursday, 08'th Apr 2021
Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study evaluating baricitinib plus standard of care (SoC) versus placebo p
Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal
07:01am, Thursday, 08'th Apr 2021
Eli Lilly & Co. and Incyte Corp. said Thursday a Phase 3 trial of rheumatoid arthritis treatment baricitinib plus standard of care (SoC) versus placebo plus SoC failed to meet its main goal. The trial
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
10:37am, Tuesday, 30'th Mar 2021
The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Incyte's Pemazyre Wins European Approval For Bile Duct Cancer
02:34pm, Monday, 29'th Mar 2021
The European Commission (EC) has approved Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, rare cancer that forms in the bile duct. The approval cove
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--European Commission Approves Pemazyre (pemigatinib) for Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Approval of Pemazyre (pemigatinib) in Japan for Unresectable BTC with a FGFR2 Fusion Gene, Worsening After Cancer Chemotherapy
Incyte's Jakafi failed Phase 3 clinical trial as a treatment for some severely ill COVID-19 patients
09:40am, Friday, 19'th Mar 2021
Shares of Incyte Corp. gained 1.6% in trading on Friday, the day after the company said its chemotherapy Jakafi did not meet the primary endpoint in a Phase 3 trial as a treatment for some severely il
Incyte's Ruxolitinib Fails To Beat Placebo In Improving Mortality In Critically-Ill COVID-19 Patients
07:12am, Friday, 19'th Mar 2021
Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients on mechanical
